Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting

Joseph J. Palamar, Silvia S. Martins, Mark K. Su, Danielle C. Ompad

Research output: Contribution to journalArticle

Abstract

Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US. Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old. Results: 1.2% of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users. Conclusion: This the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.

Original languageEnglish (US)
Article number5729
Pages (from-to)112-119
Number of pages8
JournalDrug and Alcohol Dependence
Volume156
DOIs
StatePublished - Nov 1 2015
Externally publishedYes

Fingerprint

Hallucinogens
Cannabinoids
Pharmaceutical Preparations
Tryptamines
Phenethylamines
N-Methyl-3,4-methylenedioxyamphetamine
Lysergic Acid Diethylamide
Psychotropic Drugs
Street Drugs
Cocaine
Names
Research Personnel
Health
Surveys and Questionnaires

Keywords

  • Novel psychoactive drugs
  • Novel psychoactive substances
  • Phenethylamines
  • Synthetic cannabinoids
  • Synthetic cathinones
  • Tryptamines

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Self-reported use of novel psychoactive substances in a US nationally representative survey : Prevalence, correlates, and a call for new survey methods to prevent underreporting. / Palamar, Joseph J.; Martins, Silvia S.; Su, Mark K.; Ompad, Danielle C.

In: Drug and Alcohol Dependence, Vol. 156, 5729, 01.11.2015, p. 112-119.

Research output: Contribution to journalArticle

@article{21f7c7977afb4661920e2ec5dc47303d,
title = "Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting",
abstract = "Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US. Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old. Results: 1.2{\%} of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users. Conclusion: This the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.",
keywords = "Novel psychoactive drugs, Novel psychoactive substances, Phenethylamines, Synthetic cannabinoids, Synthetic cathinones, Tryptamines",
author = "Palamar, {Joseph J.} and Martins, {Silvia S.} and Su, {Mark K.} and Ompad, {Danielle C.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.drugalcdep.2015.08.028",
language = "English (US)",
volume = "156",
pages = "112--119",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Self-reported use of novel psychoactive substances in a US nationally representative survey

T2 - Prevalence, correlates, and a call for new survey methods to prevent underreporting

AU - Palamar, Joseph J.

AU - Martins, Silvia S.

AU - Su, Mark K.

AU - Ompad, Danielle C.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US. Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old. Results: 1.2% of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users. Conclusion: This the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.

AB - Background: In recent years, there has been an increase in emergence and use of novel psychoactive substances (NPS) in the US and worldwide. However, there is little published epidemiological survey data estimating the prevalence of use in the US. Method: Data on self-reported NPS use came from the National Survey of Drug Use and Health (2009-2013), a national representative sample of non-institutionalized individuals in the US. Subjects were asked to provide names of (non-traditional) drugs they used that they were not specifically asked about. We examined lifetime prevalence and sociodemographic correlates of self-reported use of new and uncommon synthetic drugs (NPS) among subjects ages 12-34-years-old. Results: 1.2% of subjects self-reported any use of the 57 NPS we examined. Use of psychedelic tryptamines (primarily DMT) was most common, followed by psychedelic phenethylamines (e.g., 2C series) and synthetic cannabinoids. Prevalence of self-reported use of NPS increased from 2009 to 2013 and use was most common among males, whites, older subjects, those of lower income, and among those residing in cities. Lifetime use of various other illicit drugs (e.g., LSD, cocaine, ecstasy/MDMA) was highly prevalent among NPS users. Conclusion: This the first study reporting on use of a variety of NPS in a nationally representative US sample; however, use appears to be underreported as other national data suggest higher rates of NPS (e.g., synthetic cannabinoid) use. Developing more adaptable survey tools and systematically assessing NPS use would allow researchers to ask about hundreds of NPS and improve reporting as new drugs continue to rapidly emerge.

KW - Novel psychoactive drugs

KW - Novel psychoactive substances

KW - Phenethylamines

KW - Synthetic cannabinoids

KW - Synthetic cathinones

KW - Tryptamines

UR - http://www.scopus.com/inward/record.url?scp=84946489216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946489216&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2015.08.028

DO - 10.1016/j.drugalcdep.2015.08.028

M3 - Article

C2 - 26377051

AN - SCOPUS:84946489216

VL - 156

SP - 112

EP - 119

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

M1 - 5729

ER -